Danish bank eyes uncertainties for Demant in 2022
A sales halt of cochlear implants and predicted negative growth in France are behind some of the doubts about Demant’s 2022 guidance, writes an analyst from Jyske Bank.
by marketwire, translated by daniel pedersen
Danish bank Jyske Bank regards hearing aid manufacturer Demant’s half-year results from 2021 in a positive light, and therefore also the company’s full-year results, but several factors have caused some concerns about the company’s expectations for 2022, writes the bank’s senior equity analyst, Janne Vincent Kjær.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Demant's surgical division loses president of 13 years
For subscribers
.jpg&w=384&q=75)
